International Journal of Hematology

, Volume 92, Issue 4, pp 579–586

Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka

Authors

  • Tsutomu Kobayashi
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
  • Kazuho Shimura
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
    • Department of HematologyAiseikai Yamashina Hospital
  • Teruaki Akaogi
    • Department of HematologyKyoto Second Red Cross Hospital
  • Eri Kawata
    • Department of HematologyKyoto Second Red Cross Hospital
  • Miki Kiyota
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
    • Department of HematologyKyoto Second Red Cross Hospital
  • Takashi Tanaka
    • Department of HematologyKyoto Second Red Cross Hospital
  • Yuri Kamitsuji
    • Department of HematologyMatsushita Memorial Hospital
  • Satoshi Murakami
    • Department of HematologyKyoto Social Insurance Hospital
  • Mayumi Hatsuse
    • Department of HematologyKyoto Social Insurance Hospital
  • Akira Okano
    • Department of HematologyKyoto Social Insurance Hospital
  • Toshiki Iwai
    • Department of HematologyKyoto First Red Cross Hospital
  • Satomi Ueda
    • Department of HematologyKyoto First Red Cross Hospital
  • Masahiko Koshida
    • Department of HematologyKyoto First Red Cross Hospital
  • Hitoji Uchiyama
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
  • Yosuke Matsumoto
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
  • Hiroto Kaneko
    • Department of HematologyAiseikai Yamashina Hospital
  • Nobuhiko Uoshima
    • Department of HematologyMatsushita Memorial Hospital
  • Yutaka Ueda
    • Department of HematologyKyoto First Red Cross Hospital
  • Yutaka Kobayashi
    • Department of HematologyKyoto Second Red Cross Hospital
  • Chihiro Shimazaki
    • Department of HematologyKyoto Social Insurance Hospital
  • Shigeo Horiike
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
  • Masafumi Taniwaki
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
Original Article

DOI: 10.1007/s12185-010-0696-4

Cite this article as:
Kobayashi, T., Kuroda, J., Shimura, K. et al. Int J Hematol (2010) 92: 579. doi:10.1007/s12185-010-0696-4

Abstract

We conducted a retrospective collaborative investigation of bortezomib (Bor) plus dexamethasone (Dex) therapy (BD Tx) for 88 relapsed or refractory (Rel/Ref) MM patients at six institutes. One cycle BD Tx comprised of Bor (1.3 mg/m2/day) on days 1, 4, 8 and 11, and Dex on days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days, and the mean number of BD Tx cycles was 3. The overall response rate was 66.9%, the median overall survival (OS) was 510 days, and the median progression-free survival (PFS) was 113 days. Attainment of partial response (PR) with the first course of BD Tx associated with the longer OS and PFS and late good responder, while no patient who did not achieve PR with the first cycle attained better than very good PR (VGPR) with the subsequent BD Tx. Patient age of less than 64 years old also associated with the longer OS and PFS. In addition, both an earlier disease stage and Dex dosage had a significant impact on OS, while the attainment of VGPR within 2 cycles had a significantly longer PFS. Earlier BD Tx courses may be predictive for the subsequent therapeutic pathway of Rel/Ref MM.

Keywords

BortezomibMultiple myelomaRelapse

Supplementary material

12185_2010_696_MOESM1_ESM.tif (99 kb)
Impact of the number of regimen prior to BD on OS and PFS for BD Tx. Kaplan-Meier plots of OS (a) and PFS (b) according to the number of prior regimens 1-2 (solid line), 3-5 (dotted line) and 6 or more (gray line) regimens (TIFF 98 kb)
12185_2010_696_MOESM2_ESM.tif (123 kb)
Supplementary material 2 (TIFF 122 kb)
12185_2010_696_MOESM3_ESM.tif (109 kb)
Supplementary material 3 (TIFF 108 kb)

Copyright information

© The Japanese Society of Hematology 2010